Generics & Biosimilars | Association for Accessible Medicines
In the News - View AAM CEO Dan Leonard's blog on the essential role generic drugs play during COVID-19
  • My Prescription for Savings. It’s time for Congress to take meaningful action to lower prescription drug costs with the Prescription for Savings. Patients win when market-based competition from FDA-approved generics and biosimilars deliver savings at the pharmacy counter.
    AAM’s Recommendations to #SecureOurMeds
    Congress can take meaningful action to lower prescription drug costs. AAM’s Prescription for Savings outlines several solutions to secure patient access to generics and biosimilar medicines.
  • Dr. Janet Woodcock, Acting Commissioner of the Food and Drugs Administration at Access! 2021 - AAM Annual Meeting
    FDA Acting Commissioner Janet Woodcock to Speak at Access!
    An inspired choice to keynote this year’s conference, Dr. Woodcock is sure to bring new ideas and fresh insights to the table as we move into a critical time for our industry.
  • SecureOurMeds
    Congress Can Help to Secure Our Meds
    Generic and biosimilar medicines are essential to treating millions of patients. Together, we can take steps to secure patient access no matter what challenges may arise.
  • Secure Our Meds
    Plan to Secure Our Medicines
    The U.S. generics and biosimilars industry, makers of 90% of our nation's prescription medicines, has a plan to #SecureOurMeds. We already produce billions of doses domestically and our plan ensures continued patient access through COVID and beyond.
    Watch Video
  • Dan Leonard, AAM CEO and President, by his desk
    While We Await Vaccine Progress, We Can Trust in Generic Drugs
    Read AAM CEO Dan Leonard's article on the essential role generic drugs play during the COVID-19, while we await a vaccine.
  • Interactive Savings Map 2020
    Health Care Savings, State by State
    The average state saved $6.1 billion from the use of generic drugs in 2019. How much did your state save?
  • AAM Blueprint U.S. Supply Chain
    Securing the U.S. Rx Supply Chain
    The generic drug industry in the U.S. can expand domestically to increase national security, lessen dependence on any single country and create more jobs. Learn about our plan.
  • ""
    Industry Response to COVID-19
    The coronavirus (COVID-19) pandemic is disrupting everyday life around the world and imposing unprecedented stress on our health care system. Here are some responses and resources from the U.S. generics and biosimilars industry.

Association for Accessible Medicines

202.249.7100

Sign-up for Updates

Receive relevant industry news, event information and the latest resources on biosimilars and generic medicines.

Stay Connected

For the latest updates, follow us on social media.